Literature DB >> 3959241

Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection.

J M Fitzpatrick, A B West, M R Butler, V Lane, J D O'Flynn.   

Abstract

We treated 414 new patients with stage pTa, grades 1 and 2 bladder tumors by transurethral resection between 1970 and 1982. All of the patients with grade 3 or previous upper tract tumors, or who had been treated at some stage with intravesical chemotherapy were excluded. Followup for 5 or more years was available in 188 of the patients. There was a low increase in T stage (6 per cent). Of the patients followed for 5 or more years 46 per cent remained free of tumor. Only 16 per cent of the patients had multiple tumors at presentation and 20 per cent had tumors of 10 gm. or more. These factors were associated with a worse prognosis. Patients free of tumor at 3 months had an 80 per cent chance of having no further recurrences and this rate remained the same up to 2 years from the start of the disease. Patients with a recurrence at 3 months were much less likely to remain free of tumor, and had a higher chance of recurrence at every future visit.

Entities:  

Mesh:

Year:  1986        PMID: 3959241     DOI: 10.1016/s0022-5347(17)45923-4

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  22 in total

1.  Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy.

Authors:  Wassim Kassouf; Ashish M Kamat; Alexander Zlotta; Bernard H Bochner; Ronald Moore; Alan So; Jonathan Izawa; Ricardo A Rendon; Louis Lacombe; Armen G Aprikian
Journal:  Can Urol Assoc J       Date:  2010-06       Impact factor: 1.862

2.  CUA guidelines on the management of non-muscle invasive bladder cancer.

Authors:  Wassim Kassouf; Samer L Traboulsi; Girish S Kulkarni; Rodney H Breau; Alexandre Zlotta; Andrew Fairey; Alan So; Louis Lacombe; Ricardo Rendon; Armen G Aprikian; D Robert Siemens; Jonathan I Izawa; Peter Black
Journal:  Can Urol Assoc J       Date:  2015-10-13       Impact factor: 1.862

Review 3.  Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer.

Authors:  Ashish M Kamat; J Alfred Witjes; Maurizio Brausi; Mark Soloway; Donald Lamm; Raj Persad; Roger Buckley; Andreas Böhle; Marc Colombel; Joan Palou
Journal:  J Urol       Date:  2014-03-25       Impact factor: 7.450

Review 4.  Epidermal growth factor receptor and bladder cancer.

Authors:  A J Colquhoun; J K Mellon
Journal:  Postgrad Med J       Date:  2002-10       Impact factor: 2.401

5.  Bladder cancer in 156 patients aged eighty years or more.

Authors:  J M Fitzpatrick; M Durazi; M R Butler; V Lane; J D O'Flynn
Journal:  Ir J Med Sci       Date:  1987-09       Impact factor: 1.568

Review 6.  Prognostic factors in superficial bladder cancer.

Authors:  D K Chopin; Z Popov; V Ravery; J Bellot; A Hoznek; J J Patard; C C Abbou; M Colombel
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

7.  Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer.

Authors:  Catherine M Seager; Anna M Puzio-Kuter; Trushar Patel; Shalini Jain; Carlos Cordon-Cardo; James Mc Kiernan; Cory Abate-Shen
Journal:  Cancer Prev Res (Phila)       Date:  2009-12-01

Review 8.  Superficial bladder carcinoma. Factors affecting the natural history.

Authors:  J M Fitzpatrick
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

9.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

10.  Intravesical epirubicin in the prophylaxis of superficial bladder cancer.

Authors:  F Sengör; M Beysel; K Erdoğan; A Erol; D Tuzluoğlu
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.